A multispecific molecule comprising at least two non-contiguous polypeptide chains and comprising: (a) a first antigen binding moiety, (b) a second ABM that does not bind to the same epitope as the first ABM, and (c) a heterodimerization domain comprising: - a first polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRα constant domain or fragment thereof; and - a second polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRβ constant domain or fragment thereof; wherein: (i) the first ABM is connected, optionally via a linker, to the first polypeptide chain; (ii) the second ABM is connected, optionally via a linker, to the second polypeptide chain; (iii) the TCRα constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158 or at least 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1; and/or (iv) the TCRβ constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159 or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2. (a) a first antigen binding moiety, (b) a second ABM that does not bind to the same epitope as the first ABM, and (c) a heterodimerization domain comprising: - a first polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRα constant domain or fragment thereof; and - a second polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRβ constant domain or fragment thereof; wherein: (i) the first ABM is connected, optionally via a linker, to the first polypeptide chain; (ii) the second ABM is connected, optionally via a linker, to the second polypeptide chain; (iii) the TCRα constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158 or at least 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1; and/or (iv) the TCRβ constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159 or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2. - a first polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRα constant domain or fragment thereof; and - a second polypeptide chain comprising an immunoglobulin CH2 domain connected, optionally via a linker, to a TCRβ constant domain or fragment thereof; wherein: (i) the first ABM is connected, optionally via a linker, to the first polypeptide chain; (ii) the second ABM is connected, optionally via a linker, to the second polypeptide chain; (iii) the TCRα constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158 or at least 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1; and/or (iv) the TCRβ constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159 or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2. (i) the first ABM is connected, optionally via a linker, to the first polypeptide chain; (ii) the second ABM is connected, optionally via a linker, to the second polypeptide chain; (iii) the TCRα constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158 or at least 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1; and/or (iv) the TCRβ constant domain or fragment thereof comprises or consists of at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159 or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2.